Concentration of Resources on Priority Therapeutic Areas
First written in FY2016. 30 of 37 entries say "Restated". Latest entry: 2026-08-03.
0 other companies' latest entry also says "Restated".
- 2026-08-03RestatedEarnings
「During the first quarter of the current consolidated cumulative period, the pharmaceutical-related business continued to actively provide information centered on core products, with cardiovascular medicine, gastroenterology, obstetrics and gynecology, and psychiatry as its priority areas.」
Reconfirms the focus on 4 priority areas and information provision activities centered on core products. - FY2026RestatedAnnual report
「During the current consolidated fiscal year, the pharmaceutical-related business continued to actively conduct information-provision activities centered on core products, with cardiovascular medicine, gastroenterology, obstetrics and gynecology, and psychiatry as its priority areas.」
We continue to pursue a policy of concentrating resources in priority therapeutic areas and conducting information activities centered on our core products. - FY2026-H1RestatedAnnual report
「In the pharmaceutical-related business during the six-month period ended September 2024, we continued to actively conduct information activities centered on our core products, with cardiovascular medicine, gastroenterology, obstetrics and gynaecology, and psychiatry as priority areas.」
We continue to concentrate resources in the 4 priority areas of cardiovascular medicine, gastroenterology, obstetrics and gynaecology, and psychiatry, and conduct information activities centered on our core products. - FY2025RestatedAnnual report
「In the pharmaceutical-related business during the current consolidated fiscal year, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, and actively conducted information activities centered on our core products.」
We continue to concentrate resources in 4 priority therapeutic areas and conduct information activities centered on our core products. - FY2025-H1RestatedAnnual report
「During the interim consolidated accounting period, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted information-provision activities centered on core products.」
We continue to concentrate resources in 4 priority areas and conduct information activities centered on our core products. - FY2024AdvancedAnnual report
「In the pharmaceutical-related business during the current consolidated fiscal year, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, and actively conducted information activities centered on our core products. In the healthcare business, we worked to develop the market by promoting marketing based on strong support from dermatologists, obstetricians and gynaecologists, nurses and others.」
We continued to concentrate resources in 4 priority areas and advanced our focus on gastroenterology by launching 4 new products during the year. - FY2024-Q3RestatedAnnual report
「During the first 9 months of the current fiscal year, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted information-provision activities centered on core products.」
We continue to concentrate resources in 4 priority areas and conduct information activities centered on our core products. No addition of a new priority area is stated. - FY2024-Q2AdvancedAnnual report
「In addition, we have been marketing the ulcerative colitis treatment Cortiment since September 2023.」
It describes specific commercialization progress through the launch of Cortiment in gastroenterology, a priority area. - FY2024-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted information-provision activities centered on core products.」
We continue to concentrate resources in 4 priority areas and conduct information activities centered on our core products. - FY2023AdvancedAnnual report
「We introduced 2 products, the anti-IL-23p19 monoclonal antibody Omvoh and the oral steroid FE999315, both treatments indicated for ulcerative colitis, thereby strengthening gastroenterology, a priority area.」
The introduction of 2 products provides a specific means of strengthening gastroenterology, a priority area. - FY2023-Q3AdvancedAnnual report
「Through the two products, we will expand treatment options for ulcerative colitis and work to strengthen the gastroenterology business.」
It describes specific measures to strengthen gastroenterology, a priority area, through licensing agreements for 2 new products. - FY2023-Q2RestatedAnnual report
「During the first six months of the current fiscal year, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted activities to provide academic information, centered on core products.」
We continue to concentrate resources in 4 priority areas and conduct medical information activities centered on our core products. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, the pharmaceutical-related business concentrated resources on the priority areas of “cardiovascular medicine, obstetrics and gynecology, psychiatry, and gastroenterology” and actively conducted activities to provide academic information, centered on core products.」
We continue to concentrate resources in 4 priority areas and conduct medical information activities centered on our core products. - FY2022RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products.」
We continue to concentrate resources in 4 priority areas and conduct medical information activities centered on our core products. - FY2022-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products.」
We continue to concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, among others, and conduct medical information activities centered on our core products. - FY2022-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products.」
We continue to concentrate resources in priority therapeutic areas and conduct medical information activities centered on our core products. - FY2022-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products.」
We continue to concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, among others, and conduct medical information activities centered on our core products. - FY2021ReframedAnnual report
「As our highest-priority task, in our core pharmaceutical business we will concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, among others, and focus on new drugs to maximize earnings.」
The highest-priority tasks in the 21-23 Medium-Term Management Plan explicitly identify 4 areas: cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, without including dermatology, which had been listed previously. Meanwhile, the discussion of operating results states that resources are concentrated in 5 areas, including dermatology. - FY2021-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority areas centered on 5 therapeutic areas and conduct medical information activities centered on our core products. - FY2021-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority areas centered on 5 therapeutic areas and conduct medical information activities centered on our core products. - FY2021-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority areas centered on 5 therapeutic areas and conduct medical information activities centered on our core products. - FY2020RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority areas centered on 5 therapeutic areas and conduct medical information activities. - FY2020-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and conduct medical information activities centered on our core products. - FY2020-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, and conduct medical information activities centered on our core products. - FY2020-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, and conduct medical information activities centered on our core products. - FY2019RestatedAnnual report
「As our highest-priority task, in our core pharmaceutical business we will concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and focus on new drugs to maximize earnings.」
We continue to concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, and focus on new drugs. - FY2019-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and conduct medical information activities centered on our core products. - FY2019-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and conduct medical information activities centered on our core products. - FY2019-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority areas including gastroenterology and conduct medical information activities centered on our core products. - FY2018ReframedAnnual report
「We reviewed all the priority areas in our core pharmaceutical business and designated gastroenterology, strengthened by new drugs, as a new priority area. As our highest-priority task, we will concentrate resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and focus on new drugs to maximize earnings.」
It presents a revised configuration of priority areas, adding gastroenterology to the previous areas. - FY2018-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority therapeutic areas and conduct medical information activities centered on our core products. - FY2018-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority therapeutic areas and conduct medical information activities centered on our core products. - FY2018-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority therapeutic areas and conduct medical information activities centered on our core products. - FY2017-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority therapeutic areas and conduct medical information activities centered on our core products. - FY2017-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority therapeutic areas and conduct medical information activities centered on our core products. - FY2017-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to concentrate resources in priority therapeutic areas and conduct medical information activities centered on our core products. - FY2016First statedAnnual report
「We concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
A specific business management policy for the pharmaceutical-related business.